17:26 EDT SAB Biotherapeutics (SABS) files to sell 250M shares of common stock for holders
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics price target lowered to $12 from $20 at Chardan
- SAB Biotherapeutics Reports Increased Losses Amid Funding Boost
- SAB Biotherapeutics Secures $175M Funding, Paving Way for Phase 2b Diabetes Trial and Justifying Buy Rating
- SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year
- SAB Biotherapeutics Secures $175M Investment, Strengthening Financial Position and Advancing Type 1 Diabetes Treatment